APOGEPHA International

For over 25 years, we have been continuously and successfully expanding our international network for the marketing and distribution of our proprietary drug development containing the active ingredient propiverine for the treatment of bladder weakness (overactive bladder and neurogenic detrusor hyperactivity) in adults and children under the brands Mictonorm®, Detrunorm®, Mictoryl® and Propinorm®.

We are very proud that many renowned companies in more than 20 countries in Europe, Asia, Africa, North America, Latin America and South America are among our cooperation partners.

Our product is manufactured exclusively in Germany. We are committed to supporting ‘Made in Germany’ and thus guarantee excellent quality.

 

[Translate to English:] Zwei Mitarbeiter von APOGEPHA lächeln freundlich.

Log-in for sales partners

We have compiled an extensive collection of publications, materials and information for our international partners in the partner portal.

Go to Partner Portal

New Countries and Products

Our country map shows you which countries APOGEPHA already has distribution partners in.

World map showing the countries in which Apogepha distributes its products. The map provides an overview of the countries in which Apogepha distributes its products or where market entry is imminent. Information on countries and products can also be accessed via a list view, without using the map.
  • Products on the market / market entry imminent
  • Currently no cooperation partners

Our markets at a glance:

    • Mictonorm® 15 mg
    • Mictonorm® XL 30 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictonet® 5 mg
    • Mictonorm® 15 mg
    • Mictonorm® Forte 45 mg
    • Mictonorm® Uno 30 mg

    • Mictonorm® 30 mg

  • To our products in Germany

  • Bagdad
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg
    Kurdistan
    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Detrunorm® XL 30 mg
    • Detrunorm® XL 45 mg

    • Mictonorm® 15 mg
    • Mictonorm® 30 mg
    • Mictonorm® 45 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictoryl® 30 mg
    • Mictoryl® 45 mg
    • Mictoryl® Pediatric 5 mg

    • Detrunorm® 15 mg
    • Detrunorm® XR 30 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictonorm® 15 mg
    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictonorm® 15 mg

    • Propinorm® 30 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictonorm® OD 30 mg
    • Mictonorm® OD 45 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

    • Mictonet® 5 mg
    • Mictonorm® 30 mg
    • Mictonorm® 45 mg

    • Mictonorm® 15 mg

    • Mictonorm® 30 mg
    • Mictonorm® forte 45 mg

    • Detrunorm® 15 mg
    • Detrunorm® Paed 5 mg
    • Detrunorm® XL 30 mg

    • Mictonetten® 5 mg
    • Mictonorm® 15 mg
    • Mictonorm® Uno 30 mg
    • Mictonorm® Uno 45 mg
    • Pivinorm®

    • Mictonorm® 15 mg
    • Mictonorm® 5 mg
    • Mictonorm® SR 30 mg
    • Mictonorm® SR 45 mg

    • Mictonorm® 5 mg
    • Mictonorm® XL 30 mg
    • Mictonorm® XL 45 mg

APOGEPHA is constantly expanding its portfolio and welcomes new cooperation partners with a focus on urology/gynaecology in countries where it is not yet represented.

We are also seeking new products that align perfectly with our core competencies.

Please contact us if you are interested or have any questions about new countries or new products!

Contact

APOGEPHA Arzneimittel GmbH

Kyffhäuserstr. 27
01309 Dresden
Germany

Stefanie Mandel

Head of International Alliances